Compare Recursion Pharmaceuticals Inc (RXRX) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs TKO Group Holdings Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B), while TKO Group Holdings Inc trades at $191 (market cap $14.28B). The key difference: TKO Group Holdings Inc is far larger — about 7.7× Recursion Pharmaceuticals Inc's market cap, and TKO Group Holdings Inc pays a 1.62% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | TKO | |
|---|---|---|
Market Cap | $1.86B | $14.28B |
Sector | Health | Technology |
52-Week High | $6.79 | $224.96 |
52-Week Low | $2.84 | $176.49 |
Enterprise Value | $1.38B | $18.64B |
Dividend Yield | — | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
TKO trades at $195.32, up 5.01% today, with a bullish technical outlook and strong analyst support. Recent Q2 2026 earnings showed revenue growth to $1.5 billion, though EPS missed expectations. The company benefits from media rights strength in UFC and WWE, with revenue projected to rise to $5.3 billion in 2026. Positive sentiment is driven by dividend declarations and conference participation.
The outlook is positive with a consensus price target of $228.17, implying 17% upside. Risks include earnings volatility and competitive pressures in sports entertainment. Institutional ownership trends and bullish analyst ratings (89% buy) support a favorable investment case, but investors should monitor execution on guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
